ProMIS Neurosciences Reports Financial Results and Progress
U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, enhancing program’s potential for priority review.
PRECISE-AD Phase 1b Trial in Alzheimer’s Disease Progressing on Schedule: Over 50% enrolled, no cases of ARIA and no patient dropouts to date.
Strengthened Financial Position with $21.6 Million in Gross Proceeds Raised in July 2025.
ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology firm aimed at developing antibody therapeutics for addressing neurodegenerative diseases, has shared its financial results for the second quarter of 2025.
Chief Executive Officer Neil Warma expressed pride in the team's commitment and execution over the last six months, highlighting a recent breakthrough in their clinical trials. He pointed out that as of mid-August, more than 50% of the 128 patients needed for the PRECISE-AD trial have been enrolled, demonstrating strong recruitment progress. Notably, there have been no reported cases of amyloid-related imaging abnormalities (ARIA) such as brain swelling, reinforcing the potential safety of their candidate PMN310.
Furthermore, the FDA's Fast Track designation for PMN310 emphasizes the pressing need for effective Alzheimer’s therapies. With this regulatory backing and continued positive clinical trial progress, the company successfully raised approximately $21.6 million to expedite the development of PMN310.
Corporate Highlights
EpiSelect Drug Discovery Engine
In July 2025, ProMIS showcased its innovative EpiSelect platform at the AAIC conference, presenting research on identifying protein misfolding-specific epitopes crucial for neurodegenerative therapy.
This presentation included impactful insights, such as the identification of toxic misfolded proteins that play a pivotal role in diseases like Alzheimer’s, ALS, and Parkinson’s. Utilizing this platform, ProMIS aims to create targeted therapeutic antibodies that address disease-specific misfolded protein isoforms while leaving normal variants untouched.
PMN310, the firm's lead antibody candidate, demonstrates remarkable selectivity for toxic amyloid-beta oligomers (A?O), minimizing undesirable reactions with other forms of amyloid-beta. This targeted approach is critical, as it reduces potential side effects associated with broader amyloid targeting.
ProMIS has made substantial strides in its Alzheimer’s program, demonstrating a systematic approach to addressing the pressing medical need posed by this condition.
Financial Highlights for the Second Quarter 2025
ProMIS reported cash and cash equivalents reaching $4.5 million as of June 30, 2025, a significant increase from $1.0 million in the same period in 2024. The company's financial position was bolstered by recent fundraising activities, including a Registered Direct Offering and Private Placements, securing $21.6 million in July.
Research and development expenditures for the second quarter totaled $8.7 million, a notable rise from $1.6 million year-over-year, largely driven by advancements in the PRECISE-AD trial. General and administrative expenses were also up, reaching $1.4 million, compared to $1.1 million during the same timeframe last year.
The net loss for the second quarter was reported at $10.1 million, compared to a loss of $2.6 million in the previous year, primarily attributed to increased clinical trial costs.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences operates with the mission to develop effective therapeutic antibodies for neurodegenerative disorders linked to toxic protein misfolding. Their proprietary EpiSelect™ technology is at the forefront of discovering specific epitopes present on misfolded proteins associated with Alzheimer’s, ALS, and Parkinson’s diseases.
Given the promising results from early-stage trials, particularly with PMN310, ProMIS appears well-positioned to make significant advancements in the treatment landscape for Alzheimer's disease and possibly beyond.
Frequently Asked Questions
What were ProMIS Neurosciences' financial highlights for the second quarter?
ProMIS reported cash equivalents of $4.5 million, with a significant increase in research and development spending at $8.7 million, alongside a net loss of $10.1 million.
What progress has been made in the PRECISE-AD trial?
The trial has surpassed 50% enrollment with no ARIA cases reported and continues on schedule to deliver interim results by 2026.
What is the significance of the FDA's Fast Track designation for PMN310?
This designation allows for expedited development and review, emphasizing the potential of PMN310 to provide effective treatment for Alzheimer’s disease.
How does EpiSelect enhance ProMIS's drug development efforts?
EpiSelect enables the identification of specific epitopes on toxic proteins, paving the way for targeted therapies that could lead to safer and more effective treatments.
Who can I contact for more information about ProMIS Neurosciences?
For further inquiries, contact Kaytee Bock Zafereo at katherine.bock@promisneurosciences.com.
